Obicetrapib (CETP inhibitor for dyslipidemia)

adssx · 2024-03-03T06:43:13.583Z

Yes but it takes years to reach 10% of market share. And marketing is expensive. So you can multiply the price here by 10 at least.

DeStrider · 2024-03-03T06:57:26.001Z

Bempedoic Acid and Ezetemibe are about $172/year not $2,000/year. Generic versions are available. Therefore BA +EZ is the most bang for the buck. Obicetrapib is too new to have a generic available during the time we would need it. Honestly, it’s not going to be a solution for most unless your insurance will cover it.

adssx · 2024-03-03T07:06:17.183Z

Here it says that Bempedoic acid/ezetimibe costs $2,447/y: https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10315

(By the way this price discussion is mostly relevant for the US. In Europe out of pocket drugs cost 10x less and cost near 0 if covered by the gov.)

adssx · 2024-03-03T07:13:02.900Z

Actually even more: Nexlizet for as low as $406.27 on GoodRx for 1 mo supply so $5k/y?

DeStrider · 2024-03-03T07:13:23.264Z

I bought my parents the Indian generics and had them shipped to the USA. It cost me 172 USD for 400 pills including shipping to the USA. That’s a 13 month supply.

Yes, the book price is $2,000 USD per year, but why pay that much? If you can obtain the cheaper price, that’s the one you should use. Based on my father’s results, the quality was actually just as good as the expensive non generic.

adssx · 2024-03-03T07:16:45.126Z

Ok if you buy from India but that wasn’t the point of our discussion. India doesn’t respect patent law that much and produces whatever they want. Bempedoic acid was approved in 2020 so there are no generics available in the West.

My conclusion:

As it’s cheap to produce and doesn’t require cold temperature to be shipped, obicetrapib will be available for less than $1k/y on Indian marketplaces,
In the US it will probably cost about $5k/y at launch.

adssx · 2024-03-03T07:17:31.633Z

DeStrider:

Yes, the book price is $2,000 USD per year, but why pay that much? If you can obtain the cheaper price, that’s the one you should use. Based on my father’s results, the quality was actually just as good as the expensive non generic.

Which brand did you buy btw?

DeStrider · 2024-03-03T07:18:07.695Z

I bought Brillo EZ made by Sun Pharma. Great stuff.

scta123 · 2024-03-03T14:15:04.815Z

adssx:

Here it says that Bempedoic acid/ezetimibe costs $2,447/y:

In Europe I believe out of pocket expense is around 900-1000 EUR for yearly supply (around 80 EUR for 28 tablets).

adssx · 2024-03-06T10:15:11.043Z

Interview of the CEO from yesterday: New Amsterdam Pharma is trying to revive the CETP class for cardiovascular disease

At around 4:30 he mentions all-cause mortality benefits @AnUser.

He claims that obicetrapib is superior to PCSK9i and statins because:

Oral
No food effect
Decreases Lip(a)
Decreases diabetes risk
Decreases small dense LDL more

Can’t wait for the results…

AnUser · 2024-03-06T11:14:46.241Z

adssx:

At around 4:30 he mentions all-cause mortality benefits @AnUser.

As a drug class it is possible then (this was specifically not about obicetrapib).

adssx:

He claims that obicetrapib is superior to PCSK9i and statins because:

I think to persuade clinicians (I wondered why people are so bullish on high dose statins), they need to detect an ACM benefit?

adssx · 2024-03-06T11:48:51.478Z

AnUser:

As a drug class it is possible then (this was specifically not about obicetrapib).

Yes, of course.

AnUser:

I think to persuade clinicians (I wondered why people are so bullish on high dose statins), they need to detect an ACM benefit?

I don’t think that clinicians (and behind them, most importantly, payers, so private insurers in the US and governments in the rest of the world) care about ACM. (Unfortunately) I assume that if obicetrapib 1/ reduces LDL as much as statins, 2/ reduces MACE as much as statins, 3/ is associated with fewer side effects and increased adherence, and 4/ costs less than PCSK9i then it’ll persuade clinicians.